In 2026, 25 healthcare & pharma companies have cut a combined 33,819 jobs, averaging 18.7% of workforce per company.
Healthcare and pharma layoffs in 2026 are driven by clinical trial failures, regulatory setbacks, and cost restructuring. Biotech companies like Theravance and Gossamer Bio face existential cuts after late-stage trial failures, while larger pharma firms like Merck and Viatris are optimizing for efficiency.
| Company | People Cut | % of Workforce | Date | Category |
|---|---|---|---|---|
| Takeda | 4,500 | 9.2% | COST CUT | |
| Novo Nordisk | 4,000 | 6.0% | RESTRUCTURE | |
| Viatris | 3,200 | 8.6% | COST CUT | |
| BioNTech | 1,860 | 22.0% | WEAK DEMAND | |
| GSK | 1,217 | 1.8% | RESTRUCTURE | |
| Conifer Health (Tenet) | 1,037 | 1.0% | WEAK DEMAND | |
| CorroHealth | 800 | 4.7% | RESTRUCTURE | |
| Evotec | 800 | 16.0% | RESTRUCTURE | |
| Crothall / Morrison Healthcare | 795 | 8.0% | RESTRUCTURE | |
| Wellstar Health System | 761 | 2.2% | RESTRUCTURE | |
| Health Research Inc. | 760 | 96.1% | RESTRUCTURE | |
| 24Hr HomeCare | 738 | 5.7% | RESTRUCTURE | |
| GSK | 650 | 1.0% | WEAK DEMAND | |
| AstraZeneca | 600 | 0.7% | COST CUT | |
| Trinity Health | 557 | 0.4% | RESTRUCTURE | |
| Crothall / Morrison Healthcare | 545 | 5.5% | RESTRUCTURE | |
| Owens & Minor | 419 | 3.0% | RESTRUCTURE | |
| Pfizer | 330 | 0.4% | RESTRUCTURE | |
| Novartis | 322 | 0.4% | WEAK DEMAND | |
| Family Endeavors | 307 | 11.8% | WEAK DEMAND | |
| Texas Family Initiative | 307 | 19.2% | WEAK DEMAND | |
| Medline | 304 | 0.7% | RESTRUCTURE | |
| Bristol Myers Squibb | 265 | 0.8% | COST CUT | |
| Sharp HealthCare | 260 | 1.2% | RESTRUCTURE | |
| Teva | 250 | 0.7% | RESTRUCTURE | |
| Bristol Myers Squibb | 247 | 0.7% | COST CUT | |
| Horizon BCBS NJ | 242 | 5.0% | COST CUT | |
| Alameda Health System | 240 | 4.0% | COST CUT | |
| Sanofi | 229 | 0.3% | MERGER | |
| L.A. Care Health Plan | 225 | 3.0% | COST CUT | |
| Elevance Health | 216 | 0.2% | RESTRUCTURE | |
| Health First | 214 | 2.1% | RESTRUCTURE | |
| Bristol Myers Squibb | 206 | 0.6% | COST CUT | |
| InvaGen Pharmaceuticals (Cipla) | 205 | 0.7% | COST CUT | |
| Theravance Biopharma | 200 | 50.0% | RESTRUCTURE | |
| University of Vermont Health Network | 199 | 1.3% | COST CUT | |
| Gilead Sciences | 192 | 91.9% | MERGER | |
| Replimune | 161 | 59.6% | COST CUT | |
| Cellectis | 160 | 69.9% | RESTRUCTURE | |
| Molina Healthcare | 156 | 0.9% | RESTRUCTURE | |
| Pfizer | 150 | 0.2% | WEAK DEMAND | |
| PeaceHealth | 150 | 0.9% | RESTRUCTURE | |
| Kaiser Permanente | 147 | 0.1% | RESTRUCTURE | |
| Merck | 147 | 0.2% | WEAK DEMAND | |
| MultiCare Health System | 138 | 0.5% | COST CUT | |
| Presbyterian Healthcare Services | 135 | 1.1% | RESTRUCTURE | |
| PacificSource | 134 | 8.9% | RESTRUCTURE | |
| Cigna Evernorth | 134 | 0.2% | RESTRUCTURE | |
| Artiva Biotherapeutics | 131 | 94.2% | RESTRUCTURE | |
| Novartis | 130 | 0.2% | RESTRUCTURE | |
| MedImpact Healthcare | 125 | 6.2% | MERGER | |
| Dartmouth Health | 124 | 0.8% | COST CUT | |
| Intermountain Health | 117 | 0.2% | RESTRUCTURE | |
| BioMarin Pharmaceutical | 117 | 3.6% | RESTRUCTURE | |
| Children's Mercy | 115 | 1.4% | COST CUT | |
| EyePoint | 113 | 52.8% | RESTRUCTURE | |
| Novo Nordisk | 108 | 0.2% | RESTRUCTURE | |
| TScan Therapeutics | 104 | 75.4% | RESTRUCTURE | |
| GoHealth | 103 | 12.1% | RESTRUCTURE | |
| Genentech | 103 | 0.8% | RESTRUCTURE | |
| UCare | 102 | 7.0% | RESTRUCTURE | |
| Agios Pharmaceuticals | 100 | 18.5% | RESTRUCTURE | |
| Cellares | 100 | 31.4% | WEAK DEMAND | |
| ArsenalBio | 99 | 78.0% | RESTRUCTURE | |
| Autolus Therapeutics | 98 | 13.0% | RESTRUCTURE | |
| Stanford Health Care | 95 | 0.6% | RESTRUCTURE | |
| Emergent BioSolutions | 93 | 7.9% | RESTRUCTURE | |
| Tessera Therapeutics | 90 | 36.0% | RESTRUCTURE | |
| Caribou Biosciences | 87 | 89.7% | RESTRUCTURE | |
| Johnson & Johnson | 87 | 0.1% | RESTRUCTURE | |
| AssistRx | 86 | 6.1% | RESTRUCTURE | |
| Bicycle Therapeutics | 86 | 29.9% | COST CUT | |
| Ambulnz (DocGo) | 85 | 2.4% | RESTRUCTURE | |
| MaineHealth | 83 | 0.4% | RESTRUCTURE | |
| Kootenai Health | 80 | 2.0% | COST CUT | |
| Thermo Fisher | 80 | 0.1% | RESTRUCTURE | |
| Crinetics Pharmaceuticals (Vertex) | 78 | 13.1% | MERGER | |
| John Muir Health | 78 | 1.3% | RESTRUCTURE | |
| Montrose Regional Health | 77 | 9.1% | COST CUT | |
| Gossamer Bio | 77 | 48.1% | RESTRUCTURE | |
| USC (University of Southern California) | 75 | 0.3% | RESTRUCTURE | |
| City of Hope | 73 | 0.7% | RESTRUCTURE | |
| Centene | 69 | 0.1% | RESTRUCTURE | |
| Cellares | 68 | 21.4% | WEAK DEMAND | |
| AmeriHealth Caritas | 61 | 0.6% | RESTRUCTURE | |
| Teva | 61 | 0.2% | RESTRUCTURE | |
| Blue Shield of California | 60 | 0.8% | RESTRUCTURE | |
| Johnson & Johnson | 56 | 0.0% | RESTRUCTURE | |
| Molecular Partners | 55 | 47.0% | RESTRUCTURE | |
| Blue Shield of California | 54 | 0.7% | RESTRUCTURE | |
| Merck | 54 | 0.1% | COST CUT | |
| Illumina | 51 | 0.6% | RESTRUCTURE | |
| Ascension | 51 | 0.1% | RESTRUCTURE | |
| Disc Medicine | 30 | 20.0% | RESTRUCTURE | |
| Vertex Pharma | 20 | 0.2% | RESTRUCTURE | |
| Alltrna | 19 | 34.5% | RESTRUCTURE |